Viropro Accounts Payable from 2010 to 2026

VPRO Stock  USD 0.00002  0.00  0.00%   
Viropro Accounts Payable yearly trend continues to be very stable with very little volatility. Accounts Payable is likely to drop to about 365.2 K. Accounts Payable is the amount Viropro owes to suppliers or vendors for products or services received but not yet paid for. It represents Viropro's short-term liabilities. View All Fundamentals
 
Accounts Payable  
First Reported
2010-12-31
Previous Quarter
530.2 K
Current Value
365.2 K
Quarterly Volatility
32.4 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Viropro financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Viropro's main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 1 M or Total Revenue of 689.6 K, as well as many indicators such as Price To Sales Ratio of 2.37, Dividend Yield of 0.0 or PTB Ratio of 0.8. Viropro financial statements analysis is a perfect complement when working with Viropro Valuation or Volatility modules.
  
Build AI portfolio with Viropro Stock
Check out the analysis of Viropro Correlation against competitors.
To learn how to invest in Viropro Stock, please use our How to Invest in Viropro guide.

Latest Viropro's Accounts Payable Growth Pattern

Below is the plot of the Accounts Payable of Viropro over the last few years. An accounting item on the balance sheet that represents Viropro obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Viropro are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Viropro's Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Viropro's overall financial position and show how it may be relating to other accounts over time.
Accounts Payable10 Years Trend
Very volatile
   Accounts Payable   
       Timeline  

Viropro Accounts Payable Regression Statistics

Arithmetic Mean456,189
Geometric Mean455,047
Coefficient Of Variation7.10
Mean Deviation16,778
Median461,086
Standard Deviation32,368
Sample Variance1B
Range165K
R-Value0.06
Mean Square Error1.1B
R-Squared0
Significance0.80
Slope415.48
Total Sum of Squares16.8B

Viropro Accounts Payable History

2026365.2 K
2025530.2 K
2011461.1 K
2010404.5 K

About Viropro Financial Statements

Viropro investors utilize fundamental indicators, such as Accounts Payable, to predict how Viropro Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Accounts Payable530.2 K365.2 K

Pair Trading with Viropro

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Viropro position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Viropro will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Viropro could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Viropro when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Viropro - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Viropro to buy it.
The correlation of Viropro is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Viropro moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Viropro moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Viropro can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Viropro offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Viropro's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Viropro Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Viropro Stock:
Check out the analysis of Viropro Correlation against competitors.
To learn how to invest in Viropro Stock, please use our How to Invest in Viropro guide.
You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Viropro. If investors know Viropro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Viropro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Revenue Growth
1.19
The market value of Viropro is measured differently than its book value, which is the value of Viropro that is recorded on the company's balance sheet. Investors also form their own opinion of Viropro's value that differs from its market value or its book value, called intrinsic value, which is Viropro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Viropro's market value can be influenced by many factors that don't directly affect Viropro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Viropro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Viropro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Viropro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.